(MedPage Today) — The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery.
The approval allows use in stage II/III patients with…
Source link
'Groundbreaking Option' Approved for Rectal Cancer
